English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Autoimmune Hemolytic Anaemia (AIHA) is a condition in which red blood cells (RBC) are destroyed by autoantibodies and removed from the bloodstream by the immune system before their normal lifespan is over. If the rate of hemolysis is greater than hematopoiesis, severe symptoms of acute anemia develop and patients may become decompensated. In the literature, there is no absolute contraindication to RBC transfusion for AIHA patients, as it remains a safe procedure (1). According to the recent guidelines, if a patient has cardiopulmonary symptoms due to anemia, transfusion recommended regardless of hemoglobin level(2). However, generally, clinicians avoid transfusion due to the difficulties in pretransfusion testing to provide the serologically compatible RBCs. Alloantibodies that were hidden by auto-antibodies, found in up to 40% of AIHA patients and may cause a new hemolytic status(3,4). Special tests are recommended to determine the presence of an alloantibody and proper crossmatching since triggering a new hemolytic status. In clinical practice, procedures cannot be routinely performed in all transfusion centers due to the costeffectiveness and time-consuming.

Transfusion in autoimmune hemolytic anemia: comparison of two different strategies